The Loncar Cancer Immunotherapy ETF

About the Fund

The Loncar Cancer Immunotherapy ETF is made up of a basket of companies that develop therapies to treat cancer by harnessing the body’s own immune system. Immunotherapy is a transformational field within the biotechnology space that may have a foundational impact on cancer care. By developing immunotherapies that are more effective and may deliver a better quality of life than currently available medicines, innovative immunotherapy companies may be making a difference for courageous patients who battle cancer. Our ETF seeks to support this important work and its positive impact on society.


Investment Rationale

Cancer immunotherapy has become an important sector in the biotechnology space

Cancer immunotherapy has become an important sector and is changing the way many cancers are treated. While traditional medicines like chemotherapies often give cancer a broad punch, the benefit of using immunotherapy is derived from the immune system’s dynamic nature and the way it can more precisely be tailored to fight a patient’s disease. Some immunotherapies have exhibited uncommon results in clinical trials. Today, many new classes of cancer immunotherapies are being developed. These include checkpoint inhibitors (which are already FDA approved for types of melanoma, lung, kidney, and bladder cancer), cancer vaccines, bispecific antibodies, and chimeric antigen receptor (CAR-T) technologies. With this distinct sector focus, the ETF aims to help investors capture a growth area of the biotechnology space. At the same time, it will support this method of treating cancer by providing capital to public companies that are leaders in the space.

Download Investor Materials